WASHINGTON, D.C., August 20, 2017 – At a ceremony prior to the American Chemical Society fall meeting, the ACS inducted Dr. Vincenzo Summa and Dr. Steven Harper, respectively the Vice President of Drug Discovery and the Head of Medicinal Chemistry at IRBM Science Park S.p.A., into its scientific Hall of Fame as Heroes of Chemistry, 2017. The program recognizes scientists whose innovative work in chemistry and chemical engineering led to commercial products that benefit the world.
MILAN, June 20, 2017 – IRBM announced today that a scientific consortium led by its subsidiary Promidis received a 5.6 million euro grant from the Italian region of Lombardy to discover and develop innovative cures for chronic hepatitis B, a disease which still affects a significant portion of the world population, despite the availability of a vaccine. Chronic hepatitis B is a significant burden on national health systems, and can lead to severe complications, especially in children. Continue Reading
ROME, May 18, 2017 – IRBM Science Park S.p.A., alongside other public and private institutions, has supported the activities of the HDdennomore international network, a group of organizations focused on raising awareness and support for Huntington’s disease sufferers worldwide. Continue Reading
VITERBO (VT), June 30, 2016 – IRBM’s CNCCS consortium joined the Università della Tuscia, the Italian National Research Council (CNR), and the Italian Department of Instruction, University and Research (MIUR) in announcing the joint PRONAT project, aimed at identifying bioactive agents of animal or plant origin. Continue Reading
ROME, May 6, 2016 – Piero Di Lorenzo, President and CEO of IRBM Science Park S.p.A., was awarded the prestigious “Guido Carli” prize in Rome, during the seventh edition of the award. The prize, dedicated to the Italian economist Guido Carli, is awarded to Italian citizens who have distinguished themselves in the field of entrepreneurship, journalism, research and sociology. Continue Reading
ROME, June 24, 2015 – The final results of the Italian- and European-funded AICI project (Approcci Innovativi per il Controllo delle Infezioni, Innovative Approaches for Infection Control), activated in 2013 and carried out by a network of biotech companies such as IRBM Science Park S.p.A., Angelini, Ylichron and IBN Savio, were presented at a final workshop at the Angelini Research Center in St. Palomba (RM). Continue Reading